The role of plasma angiotensin II and angiotensin-converting enzyme 2 levels on prognosis and mortality in hypertensive patients with COVID-19
| Autor: | Afsin Ipekci, Dildar Konukoglu, Altuğ Kanbakan, Sermin Borekci, Fatih Çakmak, Ibrahim Murat Bolayirli, Serap Biberoglu, Yonca Senem Akdeniz, Ibrahim Ikizceli, Seda Özkan, Seval Ürkmez |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty hypertension Coronavirus disease 2019 (COVID-19) Clinical Biochemistry ACE2 Disease-Free Survival law.invention law Intensive care Internal medicine Drug Discovery medicine Humans Prospective Studies Aged Aged 80 and over ANG II business.industry SARS-CoV-2 Mortality rate Angiotensin II Biochemistry (medical) COVID-19 Plasma levels Middle Aged Intensive care unit Survival Rate Angiotensin-converting enzyme 2 Female Plasma angiotensin ii Angiotensin-Converting Enzyme 2 business Research Article |
| Zdroj: | Biomarkers in Medicine |
| ISSN: | 1752-0371 1752-0363 |
| Popis: | Introduction: SARS-CoV-2 requires angiotensin-converting enzyme 2 (ACE2) to enter the cell. In our study, we aimed to investigate the role of angiotensin-converting enzyme 2 and angiotensin II plasma levels on prognosis and mortality in patients with isolated hypertension, patients with chronic diseases in addition to hypertension and patients with COVID-19 without comorbidities, in accordance with the use of renin–angiotensin–aldosterone system inhibitor. Materials & methods: In the study, patients diagnosed with COVID-19 were divided into three groups. Angiotensin II and ACE2 levels were compared by comorbidities, antihypertensive drugs used, intensive care hospitalization and termination of patients. The relationship between angiotensin II and ACE2 levels and service and intensive care times was investigated. Findings: A total of 218 patients were enrolled in our study, including 68 patients diagnosed with COVID-19 without comorbidities, 33 patients diagnosed with isolated hypertension and 117 patients with other chronic diseases in addition to hypertension. There was no statistically significant difference between the comorbid disease groups between angiotensin II and ACE2 levels of the patients enrolled in the study. The rate of patients admitted to the intensive care unit was 17.9%, and the mortality rate was 11.5%. Results: In our study, we did not obtain significant findings regarding angiotensin II and ACE2 levels on presentation that can be used in prognosis and mortality of COVID-19 patients and development of future treatment methods. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|